Defining and classifying terminology for medication harm: a call for consensus Nazanin FalconerMichael BarrasNeil Cottrell Review 11 October 2018 Pages: 137 - 145
The intact nephron hypothesis as a model for renal drug handling Sudeep PradhanStephen B. DuffullDaniel F. B. Wright Review 08 October 2018 Pages: 147 - 156
Systematic literature review of the methodology for developing pharmacotherapeutic interchange guidelines and their implementation in hospitals and ambulatory care settings Maria Adrover-RigoMaria-Dolores Fraga-FuentesIciar Martinez-Lopez Review 19 October 2018 Pages: 157 - 170
Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: a randomized, double-blind, placebo-controlled trial Arash GhasemiZahra GhashghaiSeyed Jalal Hosseinimehr Clinical Trial 06 October 2018 Pages: 171 - 178
Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units Ophélie MaisonCléa TardyLaure Lalande Pharmacodynamics 12 December 2018 Pages: 179 - 187
Response to sertraline is influenced by GNβ3 gene G-350A variant in patients with major depressive disorder Dena FirouzabadiNegar FirouzabadiElham Shirazi Tehrani Pharmacogenetics 15 October 2018 Pages: 189 - 194
Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies Marie-Laure BoofAbir AlatrachJasper Dingemanse Pharmacokinetics and Disposition 04 October 2018 Pages: 195 - 205
Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials Diana L. ShusterRajeev M. MenonJiuhong Zha Pharmacokinetics and Disposition 05 October 2018 Pages: 207 - 216
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment Matthew P. KosloskiHaoyu WangWei Liu Pharmacokinetics and Disposition 19 October 2018 Pages: 217 - 226
Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000–2016 Nawal FarhatNisrine HaddadDaniel Krewski Pharmacoepidemiology and Prescription 15 October 2018 Pages: 227 - 235
Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study Sara Rodríguez-MartínElisa Martín-MerinoFrancisco J. de Abajo Pharmacoepidemiology and Prescription 08 October 2018 Pages: 237 - 246
Decrease in loop diuretic treatment from 2005 to 2014 in Swedish real-life patients with chronic heart failure Pär ParénAnnika RosengrenMaria Schaufelberger Pharmacoepidemiology and Prescription Open access 15 October 2018 Pages: 247 - 254
Do older adults know the purpose of their medications? A survey among community-dwelling people Léa HoisnardBrigitte Santos-EggimannMarie Herr Pharmacoepidemiology and Prescription 17 October 2018 Pages: 255 - 263
Qualitative analysis of community pharmacists’ opinions on their involvement in reducing potentially inappropriate prescribing Christina Raae HansenStephen ByrneLaura J. Sahm Pharmacoepidemiology and Prescription 20 October 2018 Pages: 265 - 274
INN or brand name drug prescriptions: a multilevel, cross-sectional study in general practice Florent De BruyneArnaud PonçonLaurent Letrilliart Pharmacoepidemiology and Prescription 27 October 2018 Pages: 275 - 283
How to proceed with long-term anticoagulation in patient after total gastrectomy and atrial fibrillation? Tomáš BolekMatej SamošMarián Mokán Letter to the Editor 09 October 2018 Pages: 285 - 286
No alteration of voriconazole concentration by plasmapheresis in a critically ill patient Manuela VayKathrin I. FoersterGerd Mikus Letter to the Editor 22 October 2018 Pages: 287 - 288
